徐兵河, 李维廉, 邸立军. 诺维本联合顺铂治疗晚期乳腺癌的多中心临床研究[J]. 中国肿瘤临床, 2004, 31(23): 1340-1342.
引用本文: 徐兵河, 李维廉, 邸立军. 诺维本联合顺铂治疗晚期乳腺癌的多中心临床研究[J]. 中国肿瘤临床, 2004, 31(23): 1340-1342.
shu
Xu Binghe, Li Weilian, Di Lijun. Vinorelbine and Cisplatin for the Treatment of Metastatic Breast Carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 31(23): 1340-1342.
Citation: Xu Binghe, Li Weilian, Di Lijun. Vinorelbine and Cisplatin for the Treatment of Metastatic Breast Carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 31(23): 1340-1342.
shu

诺维本联合顺铂治疗晚期乳腺癌的多中心临床研究

Vinorelbine and Cisplatin for the Treatment of Metastatic Breast Carcinoma

    摘要
  • 摘要: 目的:观察诺维本和顺铂联合方案治疗晚期乳腺癌的疗效与安全性。方法:2000年6月～2002年6月采用诺维本和顺铂联合方案治疗晚期乳腺癌80例。NVB25mg/m2,第1,8天;DDP80mg/m2,分3天给药(第3～5天);21天为一周期,至少治疗2周期。中位化疗周期数3个(2～6周期)。结果:CR8例,PR41例,SD28例,PD3例,总有效率(CR+PR)61.2%,中位肿瘤进展时间(TTP)6个月。主要不良反应为胃肠道反应及骨髓抑制。Ⅲ～Ⅳ度呕吐、白细胞下降和血小板下降发生率分别为12.6%(10/80),26.8%(25/80)与2.6%(2/80)。结论:诺维本联合方案治疗晚期乳腺癌疗效好,不良反应较轻,是治疗晚期乳腺癌的较好方案。

     

    Abstract: Objective: To evaluate the efficacy and safety of combination chemotherapy with vinorelbine and cisplatin in the treatment of metastatic breast cancer(MBC). Methods： From Jun 2000 to Jun 2002, eighty patients with MBC were treated with the two drugs in combination chemotherapy. A total of 251 cycles were administered with a median of 3 cycles per patient (range 2~6). Results: The overall response rate was 61.2%, The median time to tumor progression was 6 months. The treatment was well tolerated, the main toxicity was myelosuppression and vomiting with WHO grade vomiting, neutropenia and thrombocytopenia being in 12.6N(10/80), 26.8N(25/80) and 2.6N(2/80), respectively. Conclusion： Combination chemotherapy of vinorelbine and cisplatin has good anti-tumor activity on patients with MBC, the adverse reactions are tolerable to the majority of patients, it could be considered as one of the treatment regimens for MBC.

     

    • HTML全文
    • 参考文献(1)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回